
Iovance Biotherapeutics, Inc.: shareholders and insiders
Price
$6.90
November 20, 2026Market cap $3.2B
What Ploutos Investor adds for Iovance Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Nov 13, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
No trades under these filters.
From the Form 4s insiders file with the SEC within two business days of each trade.
Insiders and their shares
Every buy and sale by IOVA's officers and directors from 2011 up to November 21, 2025, 15 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 10 more, back to 2011
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class7.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.50% | 33.37M | Jul 28, 20262 filings since Jul 17, 2025 | 13G/A |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter+328%
- Bridgewater (Dalio)In the quarter
- Point72 (Cohen)In the quarter
- Millennium Mgmt (Englander)In the quarter-78%
- AQR CapitalIn the quarter-3.3%
- Citadel Advisors (Griffin)In the quarter-44%
- Renaissance TechnologiesIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 9.16M | +328% | $136M | 0.09% |
| Bridgewater (Dalio) | 521.5K | $7.7M | 0.03% | |
| Point72 (Cohen) | 1.02M | $15M | 0.02% | |
| Millennium Mgmt (Englander) | 1.87M | -78% | $28M | 0.02% |
| AQR Capital | 3.74M | -3.3% | $56M | 0.02% |
| Citadel Advisors (Griffin) | 1.17M | -44% | $17M | 0.01% |
| Renaissance Technologies | 257.7K | $3.8M | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.7% of its shares outstanding were held short, -9.1% since the report before.
- Shares held short
- 58.93M
- 12.7%
- Since the report before64.83M on Sep 30, 2026
- -9.1%
- 4.4
- 13.31M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 54%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 38.86M
- Nov 15, 2023: Shares held short 35.59M
- Nov 30, 2023: Shares held short 34.59M
- Dec 15, 2023: Shares held short 35.28M
- Dec 29, 2023: Shares held short 36.41M
- Jan 12, 2024: Shares held short 43.27M
- Jan 31, 2024: Shares held short 41.97M
- Feb 15, 2024: Shares held short 42.98M
- Feb 29, 2024: Shares held short 46.71M
- Mar 15, 2024: Shares held short 47.43M
- Mar 28, 2024: Shares held short 46.38M
- Apr 15, 2024: Shares held short 48.98M
- Apr 30, 2024: Shares held short 50.06M
- May 15, 2024: Shares held short 51.21M
- May 31, 2024: Shares held short 49.96M
- Jun 14, 2024: Shares held short 54.63M
- Jun 28, 2024: Shares held short 56.42M
- Jul 15, 2024: Shares held short 58.94M
- Jul 31, 2024: Shares held short 61.32M
- Aug 15, 2024: Shares held short 59.33M
- Aug 30, 2024: Shares held short 57.69M
- Sep 13, 2024: Shares held short 60.29M
- Sep 30, 2024: Shares held short 59.95M
- Oct 15, 2024: Shares held short 60.34M
- Oct 31, 2024: Shares held short 59.73M
- Nov 15, 2024: Shares held short 53.99M
- Nov 29, 2024: Shares held short 56.92M
- Dec 13, 2024: Shares held short 59.33M
- Dec 31, 2024: Shares held short 61.31M
- Jan 15, 2025: Shares held short 61.98M
- Jan 31, 2025: Shares held short 63.91M
- Feb 14, 2025: Shares held short 63.60M
- Feb 28, 2025: Shares held short 59.59M
- Mar 14, 2025: Shares held short 67.30M
- Mar 31, 2025: Shares held short 75.19M
- Apr 15, 2025: Shares held short 71.37M
- Apr 30, 2025: Shares held short 74.57M
- May 15, 2025: Shares held short 77.02M
- May 30, 2025: Shares held short 86.36M
- Jun 13, 2025: Shares held short 90.96M
- Jun 30, 2025: Shares held short 96.78M
- Jul 15, 2025: Shares held short 98.63M
- Jul 31, 2025: Shares held short 67.71M
- Aug 15, 2025: Shares held short 71.36M
- Aug 29, 2025: Shares held short 71.32M
- Sep 15, 2025: Shares held short 65.70M
- Sep 30, 2025: Shares held short 72.97M
- Oct 15, 2025: Shares held short 83.61M
- Oct 31, 2025: Shares held short 95.42M
- Nov 14, 2025: Shares held short 116M
- Nov 28, 2025: Shares held short 119M
- Dec 15, 2025: Shares held short 120M
- Dec 31, 2025: Shares held short 119M
- Jan 15, 2026: Shares held short 117M
- Jan 30, 2026: Shares held short 105M
- Feb 13, 2026: Shares held short 131M
- Feb 27, 2026: Shares held short 131M
- Mar 13, 2026: Shares held short 115M
- Mar 31, 2026: Shares held short 111M
- Apr 15, 2026: Shares held short 109M
- Apr 30, 2026: Shares held short 115M
- May 15, 2026: Shares held short 107M
- May 29, 2026: Shares held short 104M
- Jun 15, 2026: Shares held short 103M
- Jun 30, 2026: Shares held short 101M
- Jul 15, 2026: Shares held short 99.89M
- Jul 31, 2026: Shares held short 99.98M
- Aug 14, 2026: Shares held short 103M
- Aug 31, 2026: Shares held short 88.14M
- Sep 15, 2026: Shares held short 87.13M
- Sep 30, 2026: Shares held short 64.83M
- Oct 15, 2026: Shares held short 58.93M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading41.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 41.0% of the shares in the reported trades were short sales, against 36.3% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 41.0%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 36.3%
- Change
- +4.7 pts
- Short sales a dayon average, of 5.33M shares
- 2.19M
- More than atof 3,666 US-listed companies, same days
- 22%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 39.7%
- Oct 15, 2026: Short sales 31.9%
- Oct 16, 2026: Short sales 48%
- Oct 19, 2026: Short sales 38.8%
- Oct 20, 2026: Short sales 38.7%
- Oct 21, 2026: Short sales 40.1%
- Oct 22, 2026: Short sales 39.1%
- Oct 23, 2026: Short sales 41.5%
- Oct 26, 2026: Short sales 35.4%
- Oct 27, 2026: Short sales 35.1%
- Oct 28, 2026: Short sales 39.5%
- Oct 29, 2026: Short sales 35.1%
- Oct 30, 2026: Short sales 30.9%
- Nov 2, 2026: Short sales 31.1%
- Nov 3, 2026: Short sales 38.1%
- Nov 4, 2026: Short sales 49.1%
- Nov 5, 2026: Short sales 43.6%
- Nov 6, 2026: Short sales 38.3%
- Nov 9, 2026: Short sales 39.6%
- Nov 10, 2026: Short sales 45.9%
- Nov 11, 2026: Short sales 45.1%
- Nov 12, 2026: Short sales 47%
- Nov 13, 2026: Short sales 35.4%
- Nov 16, 2026: Short sales 44.4%
- Nov 17, 2026: Short sales 35.4%
- Nov 18, 2026: Short sales 33.8%
- Nov 19, 2026: Short sales 39.5%
- Nov 20, 2026: Short sales 31.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Wayne P. RothbaumDirectorDirectly–
- Frederick G VogtInterim CEO & General CounselDirectly604.1K
- Merrill A McpeakDirectorDirectly320.2K
- Raj K. PuriChief Regulatory OfficerDirectly256.4K
- Daniel Gordon KirbyChief Commercial OfficerDirectly160.6K
- Igor BilinskyChief Operating OfficerDirectly142.1K
- Finckenstein Friedrich GrafChief Medical OfficerDirectly140.1K
- Iain D. DukesDirectorDirectly54.0K
- Corleen M. RocheChief Financial OfficerDirectly35.9K
- Ryan D MaynardDirectorDirectly7,500
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Wayne P. RothbaumDirector | – | 28.07M | Feb 20, 2024 | Form 4 |
| Frederick G VogtInterim CEO & General Counsel | 604.1K | – | Nov 11, 2026 | Form 4 |
| Merrill A McpeakDirector | 320.2K | – | Feb 20, 2024 | Form 4 |
| Raj K. PuriChief Regulatory Officer | 256.4K | – | Sep 8, 2026 | Form 4 |
| Daniel Gordon KirbyChief Commercial Officer | 160.6K | – | Nov 10, 2026 | Form 4 |
| Igor BilinskyChief Operating Officer | 142.1K | – | Sep 8, 2026 | Form 4 |
| Finckenstein Friedrich GrafChief Medical Officer | 140.1K | – | Jun 5, 2026 | Form 4 |
| Iain D. DukesDirector | 54.0K | – | Feb 20, 2024 | Form 4 |
| Corleen M. RocheChief Financial Officer | 35.9K | – | Nov 6, 2026 | Form 4 |
| Ryan D MaynardDirector | 7,500 | – | Nov 12, 2024 | Form 4 |
A lower bound: it counts only the 10 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.56%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.41%
- IBBiShares Biotechnology ETFWeight in the fund0.13%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.11%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.10%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.09%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.06%
- IWMiShares Russell 2000 ETFWeight in the fund0.05%
- VHTVanguard Health Care Index FundWeight in the fund0.04%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.03%
22 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 253
- Q4 2025: Managers 263
- Q1 2026: Managers 288
- Q2 2026: Managers 292
Institutional investors by quarter
The fund managers holding IOVA, quarter by quarter, from Q2 2017 to Q2 2025, 33 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 292 managers held 287M shares, worth $1.2B. During the quarter 45 opened a position, 41 closed one, 126 added and 64 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+19%
- Mhr Fund ManagementIn the quarter
- State StreetIn the quarter+40%
- Two Sigma InvestmentsIn the quarter+39%
- Vanguard Capital ManagementIn the quarter+9.5%
- Vanguard Portfolio ManagementIn the quarter+23%
- Geode Capital ManagementIn the quarter+20%
- Millennium Mgmt (Englander)In the quarter-9.4%
- Dimensional Fund AdvisorsIn the quarter+144%
- Palo Alto InvestorsIn the quarter-17%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 36.96M | +19% | $154M |
| Mhr Fund Management | 28.97M | $121M | |
| State Street | 24.48M | +40% | $102M |
| Two Sigma Investments | 19.01M | +39% | $79M |
| Vanguard Capital Management | 18.20M | +9.5% | $76M |
| Vanguard Portfolio Management | 14.39M | +23% | $60M |
| Geode Capital Management | 10.32M | +20% | $43M |
| Millennium Mgmt (Englander) | 8.53M | -9.4% | $35M |
| Dimensional Fund Advisors | 6.46M | +144% | $27M |
| Palo Alto Investors | 5.30M | -17% | $22M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Iovance Biotherapeutics's filings show?
Who buys and sells is one part of Iovance Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have IOVA's insiders bought or sold?
From Jun 3, 2026 to Nov 13, 2026 Iovance Biotherapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold IOVA?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $136M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.